Illumina
    Print Page  Close Window
Illumina Wins Infringement Suit Against Premaitha Health plc and Ariosa Diagnostics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Nov. 21, 2017-- Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Premaitha Health plc, et al. and the patent infringement suit filed against Ariosa Diagnostics, Inc., et al.

The Court found that Premaitha’s IONA test infringed EP 1 981 995, EP 2 385 143, EP 2 183 693 and EP 2 514 842, which are generally directed to the use of sequencing in non-invasive prenatal testing (NIPT). The Court also found that the gender testing component in Premaitha’s IONA test and Ariosa’s Harmony test infringe EP 0 994 963. These patents are licensed by Illumina or its wholly owned subsidiary Verinata Health, Inc.

“We are pleased that the Court ruled in our favor,” said Charles Dadswell, Senior Vice President and General Counsel at Illumina. “The Court’s judgment validates the investments Illumina has made, the value of this technology and the significant contributions of the inventors in this field.”

Illumina intends to seek all available remedies for the infringement, including damages, injunctive relief, and attorney fees.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com